SecBot SecBot
PRESS-RELEASE ·Filed Mar 30, 2026

PRAX

Praxis Precision Medicines, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor for FDA decision by September 27, 2026; approval would position PRAX as a commercial-stage CNS biotech with first-mover advantage in precision epilepsy. The Pediatric Review Voucher could be monetized for hundreds of millions, providing non-dilutive capital. Consider positioning ahead of the PDUFA date, especially if regulatory signals remain positive.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$322.19
T+0 close · Mar 30, 2026 · via day close
Latest settled
+1.74%
T+60 · $327.79
Vs SPY
−10.64%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 31 $322.19entry
  2. T+1 · 8mo ago −0.90%α −1.65% · $319.28
  3. T+5 · 7mo ago −0.61%α −4.56% · $320.22
  4. T+20 · 7mo ago −0.37%α −9.79% · $321.00
  5. T+60 · 5mo ago +1.74%α −10.64% · $327.79
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Praxis Precision Medicines announced FDA acceptance of its NDA for relutrigine, a first-in-class therapy for SCN2A and SCN8A developmental and epileptic encephalopathies, with a PDUFA target action date of September 27, 2026. The filing is supported by strong Phase 2 data showing robust seizure reduction, and the drug has multiple expedited designations including Breakthrough Therapy and Rare Pediatric Disease Designation.

Key Facts

  • FDA accepted NDA for relutrigine with priority review and PDUFA date of September 27, 2026
  • Relutrigine is first potential disease-modifying therapy for SCN2A/SCN8A DEEs, which currently have no approved targeted treatments
  • NDA supported by positive interim results from EMBOLD study, stopped early for efficacy
  • Relutrigine has Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy Designations
  • If approved, eligible for Pediatric Review Voucher, enhancing commercial value

Financial Impact

High commercial and strategic value; potential first-in-class approval in ultra-rare pediatric epilepsy with voucher eligibility

revenuemarketCapvaluation

Risk Factors

  • FDA may not approve relutrigine despite priority review
  • Safety or manufacturing issues could delay or block approval
  • Commercial uptake may be limited by ultra-rare indication size

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3264996

Track record

16 reports on PRAX

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jun 29, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $317.69 Now $310.27 +2.34% settles Feb 12
  2. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $328.13 Now $310.27 −5.44% settles Feb 11
  3. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $332.97 Now $310.27 −6.82% settles Feb 5
  4. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
  5. Nov 4, 202612d ago Press Release Neutral 1/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $288.62 Now $310.27 +7.50% settles Jan 27
  7. Jun 29, 202620w ago 8-K Bearish 6/10 Entry $334.79 to $282.12 Now $310.27 +7.32% ▲ +15.73% +18.55% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $247.98 to $351.81 Now $310.27 +25.12% ▲ +41.87% +37.47% vs SPY
  9. Jun 2, 202623w ago Press Release Neutral 1/10 Entry $278.93 to $367.85 Now $310.27 +11.24% ▲ +31.88% +29.38% vs SPY
  10. May 7, 202627w ago Press Release Bullish 8/10 Entry $333.28 to $305.51 Now $310.27 −6.90% ▼ −8.33% −12.17% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (10h 48m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 30, 2026